{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T12:33:18Z","timestamp":1786883598144,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018M3A9C8016849"],"award-info":[{"award-number":["NRF-2018M3A9C8016849"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018R1A5A2023127"],"award-info":[{"award-number":["NRF-2018R1A5A2023127"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006261","name":"Taif University","doi-asserted-by":"publisher","award":["TURSP-2020\/91"],"award-info":[{"award-number":["TURSP-2020\/91"]}],"id":[{"id":"10.13039\/501100006261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008783","name":"National Research Council of Science and Technology","doi-asserted-by":"publisher","award":["CAP-12-1-KIST"],"award-info":[{"award-number":["CAP-12-1-KIST"]}],"id":[{"id":"10.13039\/501100008783","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.bioorg.2021.105352","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T19:15:43Z","timestamp":1631387743000},"page":"105352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action"],"prefix":"10.1016","volume":"116","author":[{"given":"Ahmed","family":"Elkamhawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H.","family":"Elsherbeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sora","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizaveta","family":"Gotina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda H.","family":"Abdellattif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha A.","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungsook","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ae","family":"Nim Pae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Duk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Joo","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.105352_b0005","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrd2087","article-title":"Novel pharmacological targets for the treatment of Parkinson's disease","volume":"5","author":"Schapira","year":"2006","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"Suppl 1","key":"10.1016\/j.bioorg.2021.105352_b0010","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jnc.13691","article-title":"The clinical symptoms of Parkinson's disease","volume":"139","author":"Sveinbjornsdottir","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioorg.2021.105352_b0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/NDT.S2006","article-title":"Current approaches to the treatment of Parkinson's disease","volume":"4","author":"Jankovic","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.bioorg.2021.105352_b0020","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2004.035980","article-title":"Present and future drug treatment for Parkinson\u2019s disease","volume":"76","author":"Schapira","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bioorg.2021.105352_b0025","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1021\/tx010073b","article-title":"Interactions of Nitrogen-Containing Xenobiotics with Monoamine Oxidase (MAO) Isozymes A and B: SAR Studies on MAO Substrates and Inhibitors","volume":"14","author":"Kalgutkar","year":"2001","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bioorg.2021.105352_b0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1021\/ar00056a003","article-title":"Radical Ideas about Monoamine Oxidase","volume":"28","author":"Silverman","year":"1995","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bioorg.2021.105352_b0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.neuro.22.1.197","article-title":"MONOAMINE OXIDASE: From Genes to Behavior","volume":"22","author":"Shih","year":"1999","journal-title":"Annu. Rev. Neurosci."},{"issue":"Suppl 1","key":"10.1016\/j.bioorg.2021.105352_b0040","first-page":"S287","article-title":"Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness","volume":"147","author":"Youdim","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.105352_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2010.19.1.1","article-title":"Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents","volume":"19","author":"Youdim","year":"2010","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.bioorg.2021.105352_b0050","series-title":"International Review of Neurobiology","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-386467-3.00001-7","article-title":"Structural properties of human monoamine oxidases A and B","author":"Binda","year":"2011"},{"key":"10.1016\/j.bioorg.2021.105352_b0055","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bioorg.2021.105352_b0060","doi-asserted-by":"crossref","first-page":"9877","DOI":"10.1074\/jbc.M006972200","article-title":"Substrate and Inhibitor Specificities for Human Monoamine Oxidase A and B are Influenced by a Single Amino Acid","volume":"276","author":"Geha","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0065","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1021\/bi900413g","article-title":"Molecular and Mechanistic Properties of the Membrane-Bound Mitochondrial Monoamine Oxidases","volume":"48","author":"Edmondson","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2021.105352_b0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/PPA.S11182","article-title":"Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease","volume":"5","author":"Robottom","year":"2011","journal-title":"Patient Preference Adherence"},{"key":"10.1016\/j.bioorg.2021.105352_b0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1471-2377-11-112","article-title":"Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease","volume":"11","author":"Lohle","year":"2011","journal-title":"BMC Neurol."},{"key":"10.1016\/j.bioorg.2021.105352_b0080","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/mds.26362","article-title":"New treatments for levodopa-induced motor complications","volume":"30","author":"Rascol","year":"2015","journal-title":"Movement Disorders : Off. J. Movement Disorder Soc."},{"key":"10.1016\/j.bioorg.2021.105352_b0085","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40263-015-0249-8","article-title":"Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson\u2019s Disease","volume":"29","author":"Robakis","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bioorg.2021.105352_b0090","doi-asserted-by":"crossref","first-page":"174s","DOI":"10.1592\/phco.27.12part2.174S","article-title":"Monoamine oxidase-B inhibition in the treatment of Parkinson's disease","volume":"27","author":"Fernandez","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bioorg.2021.105352_b0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2014.02.010","article-title":"Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release","volume":"143","author":"Finberg","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2021.105352_b0100","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.105352_b0105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2217\/nmt.15.46","article-title":"Clinical pharmacology review of safinamide for the treatment of Parkinson's disease","volume":"5","author":"Fabbri","year":"2015","journal-title":"Neurodegenerative Dis. Manage."},{"key":"10.1016\/j.bioorg.2021.105352_b0110","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1212\/WNL.67.7_suppl_2.S18","article-title":"Safinamide","volume":"67","author":"Caccia","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.bioorg.2021.105352_b0115","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S1353-8020(08)70618-7","article-title":"2.207 Safinamide: Beyond MAO-B inhibition","volume":"13","author":"Caccia","year":"2007","journal-title":"Parkinsonism Related Disorders"},{"issue":"2007","key":"10.1016\/j.bioorg.2021.105352_b0120","first-page":"570","article-title":"Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome, Current opinion in investigational drugs (London","volume":"8","author":"Chazot","year":"2000","journal-title":"England"},{"key":"10.1016\/j.bioorg.2021.105352_b0125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1021\/jm970599m","article-title":"Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalkyl)amino]alkanamide Derivatives","volume":"41","author":"Pevarello","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0130","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3233\/JAD-161309","article-title":"Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)","volume":"58","author":"Nave","year":"2017","journal-title":"J. Alzheimer's Dis. : JAD"},{"key":"10.1016\/j.bioorg.2021.105352_b0135","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nm.3639","article-title":"GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease","volume":"20","author":"Jo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2021.105352_b0140","first-page":"521","article-title":"Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives","volume":"80","author":"Cesura","year":"1999","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.bioorg.2021.105352_b0145","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1016\/j.bmc.2015.08.012","article-title":"Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors","volume":"23","author":"Choi","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0150","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1016\/j.bmc.2013.05.066","article-title":"Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease","volume":"21","author":"Park","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bmc.2017.11.036","article-title":"Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy","volume":"26","author":"Yeon","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0160","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/acschemneuro.7b00050","article-title":"Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease","volume":"8","author":"Nam","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2021.105352_b0165","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/14756366.2020.1842390","article-title":"Morpholine-based chalcones as dual-acting monoamine oxidase-B and acetylcholinesterase inhibitors: synthesis and biochemical investigations","volume":"36","author":"Sasidharan","year":"2021","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bioorg.2021.105352_b0170","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/jphp.13264","article-title":"Design of enamides as new selective monoamine oxidase-B inhibitors","volume":"72","author":"Kavully","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bioorg.2021.105352_b0175","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1021\/jm501690r","article-title":"New Frontiers in Selective Human MAO-B Inhibitors","volume":"58","author":"Carradori","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0180","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1021\/acs.jmedchem.6b00527","article-title":"Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors","volume":"59","author":"Reis","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0185","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1021\/jm070677y","article-title":"Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: Safinamide and Coumarin Analogs","volume":"50","author":"Binda","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejmech.2012.11.006","article-title":"1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors","volume":"59","author":"Desideri","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0195","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/jm500729a","article-title":"Indazole- and Indole-5-carboxamides: Selective and Reversible Monoamine Oxidase B Inhibitors with Subnanomolar Potency","volume":"57","author":"Tzvetkov","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0200","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jhet.349","article-title":"Biological importance of the indole nucleus in recent years: A comprehensive review","volume":"47","author":"Sharma","year":"2010","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0205","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1021\/acs.jmedchem.7b00954","article-title":"The Rise and Fall of a Scaffold: A Trend Analysis of Scaffolds in the Medicinal Chemistry Literature","volume":"61","author":"Zdrazil","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1042\/bst0190215","article-title":"Monoamine oxidase inhibitory potencies and selectivities of 2-[N-(2-propynyl)-aminomethyl]-1-methyl indole derivatives","volume":"19","author":"Balsa","year":"1991","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bioorg.2021.105352_b0215","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ardp.201600088","article-title":"Identification of Indole-Based Chalcones: Discovery of a Potent, Selective, and Reversible Class of MAO-B Inhibitors","volume":"349","author":"Sasidharan","year":"2016","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2021.105352_b0220","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejmech.2017.09.043","article-title":"Synthesis and evaluation of new pyridyl\/pyrazinyl thiourea derivatives: Neuroprotection against amyloid-\u03b2-induced toxicity","volume":"141","author":"Park","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0225","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejmech.2018.07.068","article-title":"Pyrazinyl ureas revisited: 1-(3-(Benzyloxy)pyrazin-2-yl)-3-(3,4-dichlorophenyl)urea, a new blocker of A\u03b2-induced mPTP opening for Alzheimer's disease","volume":"157","author":"Elkamhawy","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0230","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ejmech.2017.12.045","article-title":"Synthesis and evaluation of 2-(3-arylureido)pyridines and 2-(3-arylureido)pyrazines as potential modulators of A\u03b2-induced mitochondrial dysfunction in Alzheimer's disease","volume":"144","author":"Elkamhawy","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0235","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1080\/14756366.2020.1800666","article-title":"Discovery of N-(1-(3-fluorobenzoyl)-1H-indol-5-yl)pyrazine-2-carboxamide: a novel, selective, and competitive indole-based lead inhibitor for human monoamine oxidase B","volume":"35","author":"Elkamhawy","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0240","series-title":"xPharm: The Comprehensive Pharmacology Reference","first-page":"1","article-title":"Monoamine Oxidase Inhibitors","author":"Happe","year":"2007"},{"key":"10.1016\/j.bioorg.2021.105352_b0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2021.105352_b0250","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/bkcs.10363","article-title":"Design and Synthesis of New [1,2,3]Triazolo[4,5-d]pyrimidine Derivatives as Potential Antiproliferative Agents","volume":"36","author":"Elkamhawy","year":"2015","journal-title":"Bull. Korean Chem. Soc."},{"key":"10.1016\/j.bioorg.2021.105352_b0255","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ejmech.2014.07.027","article-title":"Novel quinazoline-urea analogues as modulators for A\u03b2-induced mitochondrial dysfunction: Design, synthesis, and molecular docking study","volume":"84","author":"Elkamhawy","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0260","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2021.105352_b0265","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ejps.2017.04.015","article-title":"Design, synthesis, biological evaluation and molecular modelling of 2-(2-aryloxyphenyl)-1,4-dihydroisoquinolin-3(2H)-ones: A novel class of TSPO ligands modulating amyloid-\u03b2-induced mPTP opening","volume":"104","author":"Elkamhawy","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2021.105352_b0270","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/molecules20011031","article-title":"Synthesis and in vitro screening of phenylbipyridinylpyrazole derivatives as potential antiproliferative agents","volume":"20","author":"Al-Sanea","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2021.105352_b0275","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1359-6446(99)01451-8","article-title":"Computational methods for the prediction of \u2018drug-likeness\u2019","volume":"5","author":"Clark","year":"2000","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bioorg.2021.105352_b0280","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s11095-010-0303-7","article-title":"Lipophilicity and Its Relationship with Passive Drug Permeation","volume":"28","author":"Liu","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioorg.2021.105352_b0285","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1517\/17460441.2012.714363","article-title":"The influence of lipophilicity in drug discovery and design","volume":"7","author":"Arnott","year":"2012","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2021.105352_b0290","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jmgm.2010.03.010","article-title":"Prediction of passive blood\u2013brain partitioning: Straightforward and effective classification models based on in silico derived physicochemical descriptors","volume":"28","author":"Vilar","year":"2010","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bioorg.2021.105352_b0295","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1602\/neurorx.2.4.554","article-title":"Drug Metabolism and Pharmacokinetics, the Blood-Brain Barrier, and Central Nervous System Drug Discovery","volume":"2","author":"Alavijeh","year":"2005","journal-title":"NeuroRX"},{"key":"10.1016\/j.bioorg.2021.105352_b0300","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/17460441.2.4.469","article-title":"Ligand efficiency indices for effective drug discovery","volume":"2","author":"Abad-Zapatero","year":"2007","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2021.105352_b0305","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","article-title":"High throughput artificial membrane permeability assay for blood\u2013brain barrier","volume":"38","author":"Di","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0310","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/1568026013395100","article-title":"Physicochemical Profiling (Solubility, Permeability and Charge State)","volume":"1","author":"Alex","year":"2001","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0315","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejps.2014.06.025","article-title":"Predicting both passive intestinal absorption and the dissociation constant toward albumin using the PAMPA technique","volume":"63","author":"Bujard","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2021.105352_b0320","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejmech.2016.12.057","article-title":"Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction","volume":"128","author":"Elkamhawy","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0325","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ejmech.2018.11.009","article-title":"(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons","volume":"162","author":"Tzvetkov","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0330","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0306-4522(94)90566-5","article-title":"Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis","volume":"63","author":"Walkinshaw","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.bioorg.2021.105352_b0335","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(94)92347-7","article-title":"Oxidative damage in neurodegenerative disease","volume":"344","author":"Jenner","year":"1994","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bioorg.2021.105352_b0340","doi-asserted-by":"crossref","unstructured":"K.S. Bankiewicz, R. Sanchez-Pernaute, Y. Oiwa, M. Kohutnicka, A. Cummins, J. Eberling, Preclinical models of Parkinson's disease, Current protocols in neuroscience, Chapter 9 (2001) Unit9.4.","DOI":"10.1002\/0471142301.ns0904s09"},{"key":"10.1016\/j.bioorg.2021.105352_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2020.101752","article-title":"Advancement in the modelling and therapeutics of Parkinson's disease","volume":"104","author":"Rai","year":"2020","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.bioorg.2021.105352_b0350","doi-asserted-by":"crossref","first-page":"112911","DOI":"10.1016\/j.ejmech.2020.112911","article-title":"Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity","volume":"209","author":"Jismy","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0355","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1073\/pnas.0710626105","article-title":"Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates\/inhibitors","volume":"105","author":"Son","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.bioorg.2021.105352_b0360","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14756366.2019.1593158","article-title":"SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs","volume":"34","author":"Shalaby","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0365","unstructured":"J.H. Wu, X. Tian, W. Liu, Preparation of urea and bis-urea based compounds and analogs thereof useful in the treatment of androgen receptor mediated diseases or disorders, in: The Royal Institution for the Advancement of Learning\/McGill University, Can. 2016, pp. 256."},{"key":"10.1016\/j.bioorg.2021.105352_b0370","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14756360802205455","article-title":"Synthesis and immunosuppressive activity evaluation of substituted N-imidazolidin-2-ones and N-tetrahydropyrimidin-2(1H)-ones","volume":"23","author":"Sabourin","year":"2008","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_b0375","doi-asserted-by":"crossref","first-page":"7329","DOI":"10.1021\/acs.orglett.9b02617","article-title":"Catalytic Tandem Friedel-Crafts Alkylation\/C4-C3 Ring-Contraction Reaction: An Efficient Route for the Synthesis of Indolyl Cyclopropanecarbaldehydes and Ketones","volume":"21","author":"Turnu","year":"2019","journal-title":"Org. Lett."},{"key":"10.1016\/j.bioorg.2021.105352_b0380","first-page":"195","article-title":"A novel method of neural differentiation of PC12 cells by using Opti-MEM as a basic induction medium","volume":"41","author":"Hu","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bioorg.2021.105352_b0385","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072319","article-title":"Anti-Inflammatory and Anti-Migratory Activities of Isoquinoline-1-Carboxamide Derivatives in LPS-Treated BV2 Microglial Cells via Inhibition of MAPKs\/NF-\u03baB Pathway","volume":"21","author":"Do","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2021.105352_b0390","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bioorg.2021.105352_b0395","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105352_bib396","doi-asserted-by":"crossref","unstructured":"European Journal of Medicinal Chemistry (2015). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0223523415301859?via%3Dihub#sec2, doi:10.1016\/j.ejmech.2015.08.001.","DOI":"10.1016\/j.ejmech.2015.08.001"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682100729X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682100729X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:32:08Z","timestamp":1758616328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682100729X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":80,"alternative-id":["S004520682100729X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105352","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105352"}}